C
Celon Pharma SA
WSE:CLN
Celon Pharma SA
WSE:CLN
Price:
21.6
PLN
-0.23%
Market Cap:
zł1.2B
Balance Sheet
Balance Sheet Decomposition
Celon Pharma SA
Celon Pharma SA
Balance Sheet Decomposition is not available for
Celon Pharma SA
Celon Pharma SA
Balance Sheet
Celon Pharma SA
Celon Pharma SA
Currency: PLN
| Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & Cash Equivalents |
3
|
221
|
201
|
148
|
67
|
44
|
148
|
83
|
32
|
27
|
|
| Cash Equivalents |
3
|
221
|
201
|
148
|
67
|
44
|
148
|
83
|
32
|
27
|
|
| Short-Term Investments |
1
|
1
|
0
|
0
|
0
|
0
|
80
|
82
|
82
|
48
|
|
| Total Receivables |
20
|
27
|
33
|
40
|
46
|
41
|
27
|
34
|
48
|
52
|
|
| Accounts Receivables |
17
|
25
|
30
|
31
|
39
|
32
|
25
|
27
|
33
|
39
|
|
| Other Receivables |
4
|
2
|
3
|
8
|
7
|
9
|
3
|
7
|
15
|
13
|
|
| Inventory |
19
|
20
|
18
|
24
|
30
|
30
|
23
|
38
|
26
|
30
|
|
| Other Current Assets |
2
|
1
|
2
|
2
|
1
|
4
|
1
|
1
|
1
|
3
|
|
| Total Current Assets |
45
|
270
|
255
|
214
|
144
|
119
|
279
|
238
|
190
|
160
|
|
| PP&E Net |
101
|
112
|
135
|
191
|
243
|
331
|
329
|
342
|
334
|
312
|
|
| PP&E Gross |
101
|
112
|
135
|
191
|
243
|
331
|
329
|
342
|
334
|
312
|
|
| Accumulated Depreciation |
29
|
41
|
56
|
74
|
93
|
119
|
155
|
194
|
234
|
257
|
|
| Intangible Assets |
3
|
3
|
3
|
7
|
6
|
41
|
29
|
22
|
15
|
8
|
|
| Goodwill |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Note Receivable |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Long-Term Investments |
7
|
47
|
71
|
54
|
49
|
13
|
38
|
13
|
11
|
42
|
|
| Other Long-Term Assets |
13
|
32
|
62
|
97
|
150
|
27
|
32
|
29
|
19
|
22
|
|
| Other Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Assets |
168
N/A
|
464
+176%
|
525
+13%
|
564
+7%
|
591
+5%
|
532
-10%
|
707
+33%
|
643
-9%
|
569
-11%
|
544
-4%
|
|
| Liabilities | |||||||||||
| Accounts Payable |
14
|
6
|
6
|
9
|
7
|
20
|
13
|
18
|
11
|
16
|
|
| Accrued Liabilities |
5
|
4
|
4
|
4
|
5
|
50
|
58
|
62
|
38
|
26
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
10
|
3
|
0
|
0
|
0
|
16
|
7
|
19
|
20
|
9
|
|
| Other Current Liabilities |
8
|
1
|
9
|
6
|
14
|
27
|
9
|
16
|
17
|
17
|
|
| Total Current Liabilities |
37
|
14
|
19
|
20
|
26
|
114
|
86
|
116
|
86
|
67
|
|
| Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
9
|
8
|
7
|
6
|
8
|
|
| Deferred Income Tax |
1
|
9
|
14
|
13
|
12
|
0
|
6
|
1
|
3
|
3
|
|
| Other Liabilities |
30
|
39
|
52
|
82
|
109
|
64
|
52
|
38
|
29
|
21
|
|
| Total Liabilities |
67
N/A
|
62
-8%
|
85
+38%
|
115
+35%
|
146
+27%
|
187
+28%
|
153
-18%
|
163
+7%
|
124
-24%
|
99
-20%
|
|
| Equity | |||||||||||
| Common Stock |
3
|
5
|
5
|
5
|
5
|
5
|
5
|
5
|
5
|
5
|
|
| Retained Earnings |
100
|
131
|
149
|
171
|
172
|
335
|
522
|
467
|
435
|
436
|
|
| Additional Paid In Capital |
0
|
234
|
234
|
234
|
234
|
0
|
0
|
0
|
0
|
0
|
|
| Unrealized Security Profit/Loss |
0
|
32
|
52
|
39
|
34
|
5
|
26
|
6
|
4
|
0
|
|
| Other Equity |
3
|
0
|
0
|
0
|
0
|
0
|
1
|
2
|
2
|
4
|
|
| Total Equity |
101
N/A
|
403
+299%
|
440
+9%
|
449
+2%
|
445
-1%
|
345
-23%
|
554
+61%
|
480
-13%
|
446
-7%
|
445
0%
|
|
| Total Liabilities & Equity |
168
N/A
|
464
+176%
|
525
+13%
|
564
+7%
|
591
+5%
|
532
-10%
|
707
+33%
|
643
-9%
|
569
-11%
|
544
-4%
|
|
| Shares Outstanding | |||||||||||
| Common Shares Outstanding |
30
|
45
|
45
|
45
|
45
|
45
|
51
|
51
|
51
|
54
|
|
Switch to:
Switch to:
See Also
Discover More
